BioInvenu
Private Company
Funding information not available
Overview
BioInvenu, founded in 2018, developed a proprietary cell-based assay platform called LinkLight™ that utilized protein-protein interactions as a functional readout for drug discovery. The technology was applicable to difficult-to-drug target classes such as GPCRs, nuclear hormone receptors, receptor tyrosine kinases, and non-receptor kinases, offering a biologically relevant method for identifying modulators of these interactions. The company operated as a service and product provider, offering custom assay development, cell lines, and compound profiling services until its core assets were acquired by Reaction Biology Corporation in 2024, integrating the platform into a larger contract research organization.
Technology Platform
LinkLight™ cell-based assay platform using protein-protein interactions as a functional readout for drug discovery, applicable to GPCRs, kinases, nuclear receptors, and other targets.
Opportunities
Risk Factors
Competitive Landscape
The cell-based assay market is competitive, featuring large CROs (e.g., Eurofins, DiscoverX/Revvity), reagent giants (e.g., Thermo Fisher, PerkinElmer), and specialized biotech tool companies. LinkLight competes by offering a specific, mechanism-focused readout (PPI) for particular target classes, differentiating it from more generic calcium flux, cAMP, or reporter gene assays.